Decision Readiness Check

1. TTFields has been shown to improve outcomes on average in groups of patients with newly diagnosed glioblastoma when added to standard treatment.

2. Because TTFields improves outcomes on average, every patient who uses it will live longer.

3. Doctors can currently predict with confidence which individual patients will benefit from TTFields.

4. Researchers are still investigating whether biomarkers or tumor characteristics could help identify patients most likely to benefit.

5. Researchers have proposed several ways in which TTFields may affect cancer cells, but the relative importance of these mechanisms in patients remains uncertain.

6. Scientists have proven that TTFields works through one--and only one--biological mechanism.

7. TTFields has been studied in an open-label randomized trial in which patients and clinicians knew which treatment was being received.

8. The absence of a sham device means that the clinical trial results provide no useful evidence about TTFields.

9. Overall survival is generally considered a comparatively objective and important clinical trial outcome, although questions about trial design and interpretation may still be discussed.

10. Researchers already know that combining TTFields with immunotherapy or other new treatments will provide additional benefit.

11. Studies are examining whether TTFields may work effectively with immunotherapy, targeted therapies, chemotherapy, radiotherapy, and other treatments.

12. TTFields generally has limited systemic toxicity, but that does not mean the treatment is free of side effects or practical burdens.

13. Using TTFields may require wearing the device for much of the day, shaving the scalp, changing arrays regularly, and managing the equipment.

14. Practical matters such as skin irritation, work, travel, insurance coverage, device visibility, caregiver assistance, and daily activities may reasonably influence a patient's decision.

15. Choosing not to use TTFields necessarily means that a patient does not understand the evidence or is not committed to fighting the disease.

16. Two well-informed patients in similar medical circumstances may make different choices about TTFields because they place different importance on possible survival benefit, quality of life, treatment burden, and normalcy.